CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 844 enrolled
Drug / intervention
NKTR-118 +1 moredrug
Likely dose
NKTR-118 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01336205
NCT01336205Phase 3Completed
CompareCT.gov

An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain

AstraZeneca·interventional·Posted Apr 15, 2011·Updated Oct 20, 2014

In Brief

A Phase 3 clinical trial evaluating NKTR-118 and Usual care for Opioid-Induced Constipation (OIC). Completed, enrolled 844 participants across 169 sites.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-Induced Constipation (OIC)
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 15, 2011
Enrollment StartApr 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.2 years ago

Interventions

NKTR-118drug

25 mg oral tablet once daily

Usual caredrug

As prescribed by the investigator